Could a diabetes drug shield Teens' kidneys?

NCT ID NCT07405216

Recruiting now Disease control Sponsor: Centenario Hospital Miguel Hidalgo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dapagliflozin, a drug already used in adults to protect kidneys, can reduce protein leakage in the urine of teenagers with mild chronic kidney disease. Two hundred adolescents aged 14 to 18 will receive either the drug or a placebo for six months. The goal is to see if the drug slows kidney damage and is safe for this age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin (a diabetes drug that protects kidneys)
What this could lead to: If it works, this could provide a new treatment to slow kidney disease in teenagers, reducing the risk of kidney failure later in life.
What could go wrong: This is a small, early-phase trial in a specific population, so results may not apply broadly. The drug may not reduce protein in urine or could cause side effects like dehydration or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADOLESCENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Albuminuria chronic kidney disease chronic renal failure syndrome proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADOLESCENT ALBUMINURIA CHRONIC KIDNEY DISEASE (MILD TO MODERATE) SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS

Contacts and locations

Locations

Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes
RECRUITING

Aguascalientes, Aguascalientes, 20000, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.